Short interest for Integra Lifesciences gives investors a sense of the degree to which investors are betting on the decline of Integra Lifesciences's stock. Short interest data is updated every two weeks.

Integra Lifesciences Stock (NASDAQ:IART), Short Interest Report

Integra Lifesciences

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Long Ideas

News

Penny Stocks

Health Care

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

General

IART

IRWD

PACB

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March

Integra LifeSciences Holdings Corporation (NASDAQ: IART) agreed to acquire Acclarent Inc.

Neurosurgery Focused Integra LifeSciences Bolsters Its ENT Portfolio With $275M Acquisition Deal

Price Target

Analyst Ratings

APLS

COIN

MRVL

MSTR

RIOT

SPOT

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences Holdings Corp

<a href="https://www.globenewswire.com/Tracker?data=rUslD5UFNi4_HSN1X8VMHWmJSAkrFRW_4FN6G5ihbsXt3breejgTZFmMh81gGk1A4QCUIBgNu_qnmF9lC2BbqmV1kjt0gIdbekK7KHz7uDxU0HcZckzGKr6Y1oOcR-N1">Integra LifeSciences Holdings Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>), a leading global medical technology company, is pleased to announce that following a successful Q1 2024 U.S. relaunch of its <a href="https://www.globenewswire.com/Tracker?data=GJCSko46qDZOUnr_6hrb1eX7mXQU6W1NbbSgSd3SVNiWBEt-IT_Se2eY48GfOoe9TKbV-jzmd8rb898bm4K1bsui_jZdOZFPfGuhJx0S_ZxhUtR9vY0ku7tD_Z3CgTeUeclnYCSbnX1vHHoT2N5pJLTxQu9SbKUQoLfGhzNVXgeSaz5IgdxsnCh5hikOTUS4AQ897yX1FZhiulWNxQbRMidIKCtc4KzPQ6n6Bdjgw_vlZGSxp1YcomJYdFTb8kzlXTJa7rhwi3GvKQEKfblxOtafE8F-MFmqU7cIAp-zNco=">CereLink&#xAE; ICP Monitoring System</a>, the innovative product will be featured at the upcoming AANS Annual Scientific Meeting from May 3 through 6, 2024, in Chicago, Illinois. &nbsp;
The CereLink ICP Monitoring System provides clinicians with uncompromised advanced continuous ICP monitoring, with minimal drift, MR conditional capability, durable, flexible ICP sensors, and advanced data presentation features.1,2
"The relaunch of the CereLink ICP Monitoring System helps to address the important need for accurate monitoring of intracranial pressure, which is paramount when managing patients with traumatic brain injuries, intracranial hemorrhages, strokes and other neurological conditions," said Mike McBreen, executive vice president and president, Codman Specialty Surgical. "This milestone represents a prime example of the dedication to our mission to innovate treatment pathways to advance patient outcomes and set new standards of care."
As part of Integra's industry-leading neurosurgical portfolio of products, the CereLink ICP Monitoring System will be highlighted in booth #655 at AANS 2024. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=Kn6zUEiuSUdTKhSuXiyGAFC3d8n-nMp7bA7udVg2pqwtA8iVy_2GWF6HGbmeMalrX1kIPdr6EiuNMhv0MbZTTpALVUFZGkXStOGSRbXpBK_o4imt5CtsbX5SKK-4txxyS1G7fnVvuOVYw4ylh7B3fQ==">https://marketing.integralife.com/aans2024</a>.
References: 1. CereLink bench test shows (2 stdev) of ±2.2 mmHg over 7 days and 3.8mmHg (4 stdev) over 7 days. 2. CereLink system IFUs

Biotech

Integra LifeSciences To Spotlight CereLink Intracranial Pressure Monitoring System At The American Association Of Neurological Surgeons Annual Scientific Meeting

WIIM

Integra LifeSciences shares are trading lower. The company announced it will reschedule its Q1 financial results conference call.

Citigroup analyst Joanne Wuensch upgrades Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) from Sell to Neutral and maintains the price target from $38 to $38.

Upgrades

Citigroup Upgrades Integra Lifesciences to Neutral, Maintains Price Target to $38

<a href="https://www.globenewswire.com/Tracker?data=Ob0Fy8whqLtbBKFC68yzNQynv34l4-VtstxQULq2bYcup-vTLvzt9sP9y-ei89WfZh1rfan7-YgakX0HYuiFzayd2LuUlQ_GS4uoFp882_Uif9cU8DjefeK7EBtASmPQGGKTHml7XIGGuXrJGIiAmW-wToT5hh9kQu-rUj8ioY3vhaS4IMpPelxsuJ7PUhRXzG5wB6C0WtMFI27-aDPD2eb8MrzZP0Th7qCQNneNlHFRLJTuO_jd9FZmMaodmojz2VjQ9aC8gMvEaAvE1QlclxDnB1c_BDX5JMkImv-KgXcp4GWXK-eZhjoaAL0CRHEo">Integra LifeSciences Holdings Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>), today announced MicroMatrix&#xAE; Flex is now available commercially in the U.S. MicroMatrix Flex is a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix&#xAE; paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challenging wound areas. &nbsp;
"MicroMatrix Flex has allowed me to expand how I use UBM technology in complex wound reconstruction procedures," said Dr. Aaron Moore, acute care surgeon, Mercy Health - St. Vincent Medical Center. "In addition to the benefits of UBM technology, the flexible delivery tip addresses the need to access hard-to-reach geometries in complex wounds."
Integra's UBM products – including MicroMatrix&#xAE; UBM Particulate and Cytal&#xAE; Wound Matrix sheets – have been used in more than 360,000 procedures over the past decade. During this period, UBM has been published in more than 200 pre-clinical and clinical publications. "We're excited to be adding MicroMatrix Flex to our market-leading portfolio of dermal matrices," commented Steve Powick, senior vice president, Global Marketing, Tissue Technologies Product Division. "This innovation is the culmination of working closely with surgeons to solve meaningful treatment problems and set new standards of care."
Dr. Thomas Gilbert, vice president, Research &amp; Development and Process Technology, Tissue Technologies, added "Our UBM technology supports complex wound management, and MicroMatrix Flex allows access to otherwise ‘hidden' areas of a wound. We developed this innovation through years of research and collaboration. It further expands our comprehensive regenerative medicine offerings across Integra."
For more information, visit <a href="https://www.globenewswire.com/Tracker?data=yvsv4PH5SyVeXA8o78Aug_Z-g22icAuxwjTFE0q6CrufR1dVVQceZdO4WxyUpZep9vLwKHwVp6wPy6A5M8kmWo4ElVa3edJdCXlIO4NziEU=">www.MicroMatrixFlex.com</a>.

Integra LifeSciences Launches MicroMatrix Flex To Provide Convenient Access To Hard-To-Reach Areas In Complex Cases

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>Pacific Biosciences of California, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacb#NASDAQ">PACB</a>)</h3>
<ul>
<li>On Feb. 15, Pacific Biosciences posted a narrower-than-expected quarterly loss. &quot;Our team successfully executed its goals in 2023 and launched PacBio on a trajectory this company has never seen before,&quot; said Christian Henry, President and CEO of PacBio. &quot;We continue to build solutions across the workflow, allowing our customers to further scale on HiFi, and we are encouraged to see how researchers are already making discoveries and shifting paradigms with the power and economics of Revio and the extraordinary accuracy of Onso.&quot; The company&rsquo;s stock fell around 27% over the past five days and has a <a href="https://www.benzinga.com/quote/PACB">52-week low of $4.0050 </a>.</li>
<li>RSI Value: 28.98</li>
<li>PACB Price Action: Shares of Pacific Biosciences of California fell 4% to close at $4.1750 on Wednesday.</li>
</ul>
<h3>Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>)</h3>
<ul>
<li>On Feb. 29, Ironwood Pharmaceuticals released topline results from its pivotal Phase 3 STARS trial of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) (drugs given by routes other than the digestive tract) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF). The company&rsquo;s stock fell around 19% over the past five days. It <a href="https://www.benzinga.com/quote/IRWD"> has a 52-week low </a> of $8.07.</li>
<li>RSI Value: 21.99</li>
<li>IRWD Price Action: Shares of Ironwood Pharmaceuticals fell 7.5% to close at $8.62 on Wednesday.</li>
</ul>
<h3>Integra LifeSciences Holdings Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iart#NASDAQ">IART</a>)</h3>
<ul>
<li>On Feb. 28, Integra Lifesciences posted downbeat quarterly results. The company&rsquo;s stock fell around 8% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/IART"> low of $33.44.</a></li>
<li>RSI Value: 28.88</li>
<li>IART Price Action: Shares of Integra LifeSciences fell 1.2% to close at $36.11 on Wednesday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/24/03/37527629/kroger-broadcom-and-3-stocks-to-watch-heading-into-thursday"> Kroger, Broadcom And 3 Stocks To Watch Heading Into Thursday </a>

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and lowers the price target from $46 to $41.

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $41

5 analysts have expressed a variety of opinions on Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Integra Lifesciences, presenting an average target of $48.6, a high estimate of $55.00, and a low estimate of $44.00. This upward trend is evident, with the current average reflecting a 9.21% increase from the previous average price target of $44.50.
<img src="https://www.benzinga.com/files/images/story/2024/1709236876_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Integra Lifesciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$49.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Integra Lifesciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Integra Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Integra Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Integra Lifesciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Integra Lifesciences analyst ratings.</a>
<h2>All You Need to Know About Integra Lifesciences</h2>
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
<h3>Unraveling the Financial Story of Integra Lifesciences</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Integra Lifesciences's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -0.72%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Integra Lifesciences's net margin excels beyond industry benchmarks, reaching 5.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Integra Lifesciences's ROE excels beyond industry benchmarks, reaching 1.2%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Integra Lifesciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.52%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.07, Integra Lifesciences faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 5 Ratings For Integra Lifesciences

JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Market Outperform and lowers the price target from $55 to $49.

JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $49

Management

Integra LifeSciences' Jan De Witte To Retire As President And CEO Following Appointment Of Successor, Which Is Expected To Occur By End Of 2024. The Company Also Appointed Stuart Essig, Integra's Chairman, As Executive Chairman, Effective Immediately

Earnings

Guidance

Integra LifeSciences Forecasts Q1 Fiscal Year 2024 Adjusted EPS Of $0.53-$0.57. Versus Consensus Of $0.75

Integra LifeSciences Forecasts Q1 Fiscal Year 2024 Revenues Of $360M-$365M, Representing Reported Growth Of Approximately -5.5% To -4.1% And Organic Growth Of Approximately -5.1% To -3.7%. Versus Consensus Of $380.91M

Integra LifeSciences Forecasts Fiscal Year 2024 Adjusted EPS Of $3.15-$3.25 Versus Consensus Of $3.44

Integra LifeSciences Forecasts Fiscal Year 2024 Revenues Of $1.603B-$1.618B, Representing Reported And Organic Growth Of Approximately 4.0%-5.0%, Versus Consensus Of $1.62B

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported its Q4 earnings results on Wednesday, February 28, 2024 at 06:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Integra Lifesciences missed estimated earnings by -1.0%, reporting an EPS of $0.89 versus an estimate of $0.9.
Revenue was down $983 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.02 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Integra Lifesciences's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.78</td>
<td>0.57</td>
<td>0.74</td>
<td>0.90</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.76</td>
<td>0.71</td>
<td>0.74</td>
<td>0.94</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>387.12M</td>
<td>374.07M</td>
<td>373.21M</td>
<td>397.95M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>382.42M</td>
<td>381.30M</td>
<td>380.85M</td>
<td>398.02M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Integra Lifesciences <a href="https://www.benzinga.com/quote/IART/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Integra Lifesciences Q4 Earnings

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported quarterly earnings of $0.89 per share which missed the analyst consensus estimate of $0.90 by 1.11 percent. This is a 5.32 percent decrease over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $397.04 million which missed the analyst consensus estimate of $399.34 million by 0.58 percent. This is a 0.25 percent decrease over sales of $398.02 million the same period last year.

Integra Lifesciences Q4 Adjusted EPS $0.89 Misses $0.90 Estimate, Sales $397.04M Miss $399.34M Estimate

In the preceding three months, 7 analysts have released ratings for Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $45.71, a high estimate of $55.00, and a low estimate of $37.00. Surpassing the previous average price target of $41.60, the current average has increased by 9.88%.
<img src="https://www.benzinga.com/files/images/story/2023/1703257244_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Integra Lifesciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Kristen Stewart</td>
<td>CL King</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$37.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Integra Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Integra Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Integra Lifesciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Integra Lifesciences analyst ratings.</a>
<h2>Get to Know Integra Lifesciences Better</h2>
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
<h3>A Deep Dive into Integra Lifesciences's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Integra Lifesciences faced challenges, resulting in a decline of approximately -0.72% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Integra Lifesciences's net margin is impressive, surpassing industry averages. With a net margin of 5.1%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Integra Lifesciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.2% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.52%, the company showcases effective utilization of assets.
Debt Management: Integra Lifesciences's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.07, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 7 Takes On Integra Lifesciences

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and raises the price target from $44 to $46.

Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $46

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and raises the price target from $39 to $44.

Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $44

JMP Securities analyst David Turkaly reiterates Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Market Outperform and maintains $55 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Integra Lifesciences, Maintains $55 Price Target

Integra LifeSciences Holdings Corporation&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iart#NASDAQ">IART</a>) agreed to acquire&nbsp;Acclarent Inc. from&nbsp;Ethicon Inc, a&nbsp;Johnson &amp; Johnson&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) MedTech company, for $275 million in cash, and an additional $5 million upon the achievement of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/g36212513/integra-lifesciences-announces-definitive-agreement-to-acquire-acclarent" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">certain regulatory milestones</a>.&nbsp;
Acclarent offers medical devices for ENT procedures.
The acquisition will become part of Integra&#39;s Codman Specialty Surgical (CSS) division.&nbsp;
The ear, nose, and throat (ENT) category is a key area of strategic interest and highly complementary to the neurosurgery segment.
&quot;This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment,&quot; said Jan De Witte, president and chief executive officer of Integra LifeSciences.&nbsp;
The U.S. ENT specialty devices market is growing at 5-6% and will add approximately $1 billion to the CSS global total addressable market.&nbsp;
The Acclarent portfolio includes balloon technologies for sinus dilation, eustachian tube dilation, and surgical navigation systems.
Acclarent generated about $110 million in 2022, and gross margins aligned with Integra&#39;s company average.&nbsp;
The company maintains R&amp;D facilities in Irvine and Haifa, Israel, and uses third-party manufacturers.
Integra currently participates in the ENT category with its MicroFrance line of ENT instruments.
The transaction is expected to close by the second quarter of 2024 and be accretive to Integra&#39;s long-range plan.&nbsp;
Following the close, transition services, including the transition manufacturing services, will be provided for up to four years.&nbsp;
In its&nbsp;<a class="editor-rtfLink" href="https://investor.integralife.com/news-releases/news-release-details/integra-lifesciences-reports-third-quarter-2023-financial" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Q3</a>&nbsp;earnings release, the company had a total liquidity of approximately $1.48 billion, including $273.7 million in cash and the remainder available under its revolving credit facility.
Price Action:&nbsp;IART shares are trading lower by 0.49% at $40.72 on the last check Wednesday.

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRM – Research Report) and I...

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Integra Lifesciences (IART)

Craig Bijou, an analyst from Bank of America Securities, reiterated the Sell rating on Integra Lifesciences (IART – Research Report). The associate...

Integra Lifesciences: Sell Rating Justified by Underwhelming Financials and Leadership Concerns

In a report released yesterday, Vik Chopra from Wells Fargo maintained a Buy rating on Integra Lifesciences (IART – Research Report), with a price ...

Buy Rating on Integra Lifesciences Amidst Recovery and Growth Prospects

In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Hold rating on Integra Lifesciences (IART – Research Report). The company's s...

BTIG Sticks to Its Hold Rating for Integra Lifesciences (IART)

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Integra Lifesciences (IART – Research Report), with ...

Truist Financial Sticks to Their Hold Rating for Integra Lifesciences (IART)

Top buy-rated stocks and sell-rated stocks within Health Care - Citi

ClearBridge Small Cap Growth Strategy Q2 2024 Portfolio Manager Commentary

Jefferies analyst Matthew Taylor maintained a Buy rating on Integra Lifesciences (IART – Research Report) today and set a price target of $50.00. T...

Jefferies Sticks to Their Buy Rating for Integra Lifesciences (IART)

Warning: IART is at high risk of performing badly

Wells Fargo analyst Vik Chopra has maintained their bullish stance on IART stock, giving a Buy rating on April 22. Vik Chopra has given his Buy rat...

Buy Rating for Integra Lifesciences Amid Favorable Medicare Policy Changes

ALTM

ARLTF

CASY

CNMD

CPRX

DUOL

EXEL

FOXF

FWRD

INCY

INSM

INTA

IRDM

MEDP

MIRM

NVDA

OMCL

OSUR

PODD

RCUS

RDNT

SDGR

SHLS

SMCI

TREX

VKTX

WING

XMTR

Press Releases

Integra LifeSciences to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Legal

INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term Investors to Contact the Firm

Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

Integra LifeSciences Announces Leadership Transition Plan

Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Integra Lifesciences Holdings Corp - IART

Integra LifeSciences Completes the Acquisition of Acclarent, Inc.

Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024

Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Integra Lifesciences Stock (NASDAQ:IART), Short Interest Report

People Also Watch